Attaching Cell-Penetrating Peptides to Cancer Antibodies Boosts Internalization 4x and Cytotoxicity 6x
Conjugating tetrameric cell-penetrating peptides to cancer antibodies increased their cellular internalization up to 4-fold and boosted the cytotoxicity of antibody-drug conjugate Kadcyla by 6-fold.
Quick Facts
What This Study Found
tCPP conjugation achieved up to 4-fold elevated internalization rates for three clinical antibodies while retaining target specificity. tCPP-Kadcyla showed 6-fold increased cytotoxicity. Favorable pharmacokinetics limited off-target accumulation.
Key Numbers
4x internalization; 6x cytotoxicity for Kadcyla-tCPP; maintained specificity; improved PK; 3 antibodies tested
How They Did This
Solid-phase synthesis of tetrameric CPPs (tCPPs) conjugated to matuzumab, trastuzumab, and Kadcyla. Measured internalization rates, target specificity, pharmacokinetics, and cytotoxicity in cancer cell lines.
Why This Research Matters
Many antibody-drug conjugates underperform because they do not efficiently enter cancer cells. Boosting internalization with CPPs could make existing ADCs significantly more effective without developing entirely new drugs.
The Bigger Picture
This technology could be broadly applicable to the ADC drug class — a + billion market — by improving the intracellular delivery step that often limits their effectiveness.
What This Study Doesn't Tell Us
In vitro only — in vivo efficacy and toxicity not assessed. Off-target effects of antigen-independent internalization need careful evaluation. Manufacturing scalability of tCPP-conjugated antibodies not addressed.
Questions This Raises
- ?Would the 6-fold cytotoxicity improvement translate to better tumor responses in animal models?
- ?Does antigen-independent internalization cause off-target toxicity in vivo?
- ?Can this approach be applied to other ADCs beyond Kadcyla?
Trust & Context
- Key Stat:
- 6x more cytotoxic tCPP-modified Kadcyla was six times more effective at killing cancer cells than unmodified Kadcyla
- Evidence Grade:
- Preliminary — strong in vitro results with clinical antibodies but no in vivo validation of efficacy or safety.
- Study Age:
- Published in 2020; ADC engineering with enhanced internalization strategies continues to advance.
- Original Title:
- Improving antibody-based therapies by chemical engineering of antibodies with multimeric cell-penetrating peptides for elevated intracellular delivery.
- Published In:
- Journal of controlled release : official journal of the Controlled Release Society, 322, 200-208 (2020)
- Authors:
- Sauter, Max, Strieker, Matthias, Kleist, Christian, Wischnjow, Artjom, Daniel, Volker, Altmann, Annette, Haberkorn, Uwe, Mier, Walter
- Database ID:
- RPEP-05112
Evidence Hierarchy
Frequently Asked Questions
What are antibody-drug conjugates (ADCs)?
ADCs are cancer drugs that combine a targeting antibody (which finds cancer cells) with a cytotoxic payload (which kills them). The antibody delivers the drug directly to cancer cells, reducing side effects compared to traditional chemotherapy.
Why would adding cell-penetrating peptides help?
ADCs must enter cancer cells to release their toxic payload. Many ADCs are limited because they are not efficiently internalized. The tetrameric CPPs act like a molecular crowbar, dramatically increasing how quickly and how much antibody gets inside cancer cells.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05112APA
Sauter, Max; Strieker, Matthias; Kleist, Christian; Wischnjow, Artjom; Daniel, Volker; Altmann, Annette; Haberkorn, Uwe; Mier, Walter. (2020). Improving antibody-based therapies by chemical engineering of antibodies with multimeric cell-penetrating peptides for elevated intracellular delivery.. Journal of controlled release : official journal of the Controlled Release Society, 322, 200-208. https://doi.org/10.1016/j.jconrel.2020.03.005
MLA
Sauter, Max, et al. "Improving antibody-based therapies by chemical engineering of antibodies with multimeric cell-penetrating peptides for elevated intracellular delivery.." Journal of controlled release : official journal of the Controlled Release Society, 2020. https://doi.org/10.1016/j.jconrel.2020.03.005
RethinkPeptides
RethinkPeptides Research Database. "Improving antibody-based therapies by chemical engineering o..." RPEP-05112. Retrieved from https://rethinkpeptides.com/research/sauter-2020-improving-antibodybased-therapies-by
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.